Nanoparticles to Give New Direction to "Melanoma Therapeutics"

Melanoma is usually a type of skin cancer, which begins in melanocytes. It often develops in moles formed by melanocytes. Growing incidence of melanoma and other skin cancers continues to be one of the leading factors fueling the demand for melanoma therapeutics. The American Cancer Society estimates that approximately 87,110 new cases of melanoma will be diagnosed in 2017.

View Summary Of This Report Click Here: www.goo.gl/M2EQFp

Demand for Targeted Therapies to Witness Sharp Rise

Some of the common therapies used for melanoma treatment are immunotherapy, chemotherapy, radiation therapy, and targeted therapy. In 2016, immunotherapy accounted for the leading share. The growth of the segment can be attributed to increasing approvals of immunotherapies along with high effectiveness of drugs used in these therapies. Presence of strong pipeline for melanoma treatment is expected to contribute to the growth of the segment.

Targeted therapy is expected to exhibit a remarkable growth rate through 2025. Limited side effects and high efficiency of targeted therapies may help them emerge as the preferred treatment. Moreover, with advancements in genomics, these therapies have evolved as a boon for patients who cannot be cured by intensive cytotoxic chemotherapy. The radiation therapy segment is anticipated to register steady growth during the same period. Mounting cases of advanced melanoma and increasing utilization of radiations as adjuvant therapy after surgeries are estimated to supplement the growth of the segment. However, radiation therapies are administered only to patients in stage 4 of cancer and thus, relatively lesser used as primary treatment.

Market Insights

As per the findings of Grand View Research, Inc.; the global melanoma therapeutics market is poised to rise to a valuation of USD 12.4 billion by the end of 2025. Companies and research institutes are undertaking various R&D activities to develop innovative molecules and combinations for the treatment of melanoma. For instance, researchers from the Penn State College of Medicine developed CelePlum-777, a combination of Celecoxib and Plumbagin in a specific ratio, to kill melanoma cells. They used nanoparticles to deliver drugs directly to the cancer cells.

North America may continue to hold a prominent position in the global arena during the review period (2014 to 2025). Favorable reimbursement policies introduced by governments can propel the regional market. Some of the key players in the market are AstraZeneca; Novartis AG; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Bristol-Myers Squibb Company.

Request For Free Sample: www.goo.gl/e8D7x5

Cancer and Gastro-Intestinal Tract Diseases are Expected to Boost Parenteral Nutrition Market

The global Parenteral Nutrition Market is expected to reach USD 7.3 billion by 2024, according to a new report by Grand View Research, Inc. The increasing natality rate, the growing malnutrition coupled with the prevalence of chronic conditions such as cancer and gastro-intestinal tract diseases are expected to boost the market over the forecast period.

The presence of malnourished children in the developing countries leading to the rise in the natality rate and the rising geriatric population suffering from a deficiency of essential nutrients are some of the major factors that are expected to fuel the global parenteral nutrition market.

View Summary Of This Report Click Here: www.goo.gl/gcCWe2

According to the WHO around 40.0% patients across the world were malnourished in 2010. The study also indicated that about one-third of the patients in Europe were malnourished in 2012, thereby fueling industry growth.

According to the statistics provided by the World Bank Group, India had the highest natality rate followed by China in 2012. Moreover, a consistent increase in the rate of natality was observed in the European countries such as the U.K. and France. Therefore, Asia Pacific and Europe are expected to witness the fastest growth over the forecast.

North America is expected to witness lucrative growth due to the increase in consumer awareness paired with the increasing healthcare costs. As parenteral nutrition products are available in the home health care sector, it further facilitates the market growth due to the increasing trend in home health care. The increasing incidence of heart diseases is another vital driver. According to the WHO around 49.0% of the American population is endangered with the risk of cardiac arrest.

Further key findings from the study suggest:

• North America is expected to dominate the overall market with a revenue share of about40.0% in 2024, owing to the increasing incidences of heart diseases coupled with the rise in home health care.
• Asia Pacific and Europe are anticipated to be the fastest growing region with a CAGR of over5.5% over the forecast period. The rise in the natality rate, rising geriatric population and the growing awareness regarding the importance of nutritional value and its impact on health are the vital impact rendering drivers for the region.
• Key players of the industry include Baxter International, Inc., Hospira, Inc., B. Braun Melsungen AG, Grifols International S.A., Fresenius Kabi AG, Otsuka Pharmaceutical Factory, Inc., Actavis, Inc., Sichuan Kelun Pharmaceutical Co., Ltd. Most of these companies have been in the business for over a decade and are bringing in expertise and technological advancements that are expected to help them sustain over the forecast period.

Request For Free Sample: www.goo.gl/4Gx8oF

HIV, H1N1, and Ebola Diseases are Driving the Anti-Infective Agents Market

The global Anti-Infective Agents Market is expected to reach over USD 111.4 billion by 2024 according to a new report by Grand View Research, Inc. The rising prevalence of infectious diseases such as HIV, H1N1, and Ebola virus reflect the profound changes in behavioral patterns of communities over the recent decades. The societal changes and the increasing awareness levels amongst the healthcare professionals and the patients pertaining to these diseases are driving the anti-infective agents market.

View Summary Of This Report Click Here: www.goo.gl/QJCBNw

Organizations, such as the WHO and CDC are actively involved in spreading awareness amongst people regarding the implications of infectious diseases, which are fatal in nature and the importance of early treatment. The CDC has collaborated with the National Health Ministry (NHM) in an attempt to spread awareness and enhance the treatment rates for communicable diseases in developing countries such as Brazil, China, Nigeria, and India.

However, the introduction of novel therapeutics with increased potency and efficacy and the commercialization of pipeline products, such as commercialization of Omadacycline in 2018 for the treatment of Community Acquired Bacterial Pneumonia (CABP) in the near future, are expected to favorthe market growth.

Further key findings from the study suggest:

• The antibacterial segment was observed to account for the largest share of over 54.0% in 2015. The large market share is attributed to the fact that antibacterials are preferred as the first line of treatment for a large range of infections, the high prescription rates exhibited by this segment, and the increased accessibility of the antibacterials due to their over-the-counter status.
• The development of combination drugs to treat and prevent, serious and life-threatening infections is expected to accentuate the usage of anti-infective drugs. For instance, in 2012, Gilead Sciences, Inc. launched Stribild, which is a comprehensive treatment regimen inclusive of four drugs(cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate) used for the treatment of HIV patients without prior retroviral treatment record.
• The anti-viral agents segment is expected to grow at a swift CAGR of over 3.5% owing to the high price associated with the introduction of new potent anti-viral drugs such as Vicriviroc for HIV treatment purpose
• North America dominated the overall anti-infective agents market in terms of revenue of over25.0 billion in 2015.The rise in prevalence of infectious diseases including hospital-acquired infections in both, children and adults, and the resultant overuse of antibiotics coupled with the increased accessibility to non-prescription anti-infectives in the market are the factors responsible for its dominance.
• Asia Pacific is one of the fastest growing regional segments owing to the presence of high, unmet market demand for novel drugs, rapid improvements in healthcare infrastructure coupled with the rising awareness amongst healthcare professionals as well as patients
• Some of the major companies operating in this market are Abbott Laboratories, Gilead Sciences, Inc., Bristol-Myers Squibb Co., Merck & Co., Inc, Bayer Healthcare AG, AstraZeneca Plc, Boehringer Ingelheim, and Novartis AG.
• Effective disease management involves a range of long-term strategies such as new product development, merger and acquisitions, co-development, and expansion. For instance, in 2015, ReViral has received a funding of USD 21 million for the development of its RV521 drug by the Wellcome Trust.

Request For Free Sample: www.goo.gl/N7pjsp

Asthma Therapeutics Market To Reach $25.6 Billion By 2024

Global Asthma Therapeutics Market is expected to reach USD 25.6 billion by 2024, according to a new study by Grand View Research, Inc. 

The increasing prevalence of asthma coupled with the adoption of biologics as a long-term treatment option to treat the severe form of asthma is expected to offer this market with lucrative growth opportunities. According to the statistics published by the World Allergy Journal, in May 2014, patients suffering from asthma registered around 300 million and the number is expected to soar due to a large number of individuals inclining towards unhealthy dietary habits and sedentary lifestyles. 

View Summary Of This Report Click Here: 

www.grandviewresearch.com/industry-analysis/asthma-therapeutics-market

In addition, patent expiration of branded drugs, such as Singulair, Advair and other major drugs during the forecast period has led to a stiff generic competition, which will negatively impact the asthma therapeutics market growth in the coming years. On the contrary, the introduction of biologics is accruing towards the increasing market share of the asthma therapeutics segment, and is anticipated to continue during the forecast period. 

The enhanced demand for personalized medicine approach as opposed to the conventional medication prescription pattern for treatment of severe asthma is anticipated to aid the emergence of asthma therapeutics market in the future. In addition, development of technologically advanced products, such as pressurized metered dose inhalers and smart inhalers, equipped with sensor technology and inbuilt wireless communication system is further expected to propel the asthma therapeutics market growth in the next seven years.  

Further key findings from the study suggest:

• The anti-inflammatory drug class is expected to exhibit rapid growth at a lucrative CAGR of 3.4% over the forecast period owing to the introduction of affordable and innovative biologics targeting the severe asthma condition. In addition, the awareness gained pertaining to the benefits rendered by the biologics and monoclonal antibodies is anticipated to exhibit an upward shift in the market expansion in the coming years.
• The dry powder inhalers (DPIs) are expected to be the fastest growing segment due to the increasing adoption of these devices because of their high clinical efficiency than other inhalers. They are able to deliver both, small and large-sized drug components and dispense specialty engineered molecules. These related merits have spiked the adoption rates thereby contributing towards the risen market penetration.
• Rising number of individuals opting for alternative treatment options, such as inhaled fixed-dose combination drugs for asthma medication is anticipated to serve this market with future growth opportunities. The inhalers market is expected to grow at a CAGR of above 2.0% over the forecast period. 
• Some of the key players operating in the asthma therapeutics market include AstraZeneca Plc, Philips Healthcare, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc, Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Roche Diagnostics, and Merck& Co., Inc. 
• Market leaders are focusing on the introduction of technologically advanced devices and novel, improved biologics to gain a competitive advantage. The asthma therapeutics segment has a very strong pipeline as there are almost 100 novel molecules that are in the development phase and manufacturers are focusing on the development of personalized medication. The aforementioned factors collectively strengthen the industry growth in the near future. 
• For instance, drug molecules, such as Cinquil by Teva Pharmaceutical Industries Ltd., Lebrikizumab by Roche (Phase III), Mastinib by AB Science (Phase II/III), and Bosatria by GlaxoSmithKline Plc (Phase III), are in the development stage undergoing clinical research trials. Their commercial availability during the forecast period is expected to provide a boost to this vertical.

Request for free sample of "Asthma Therapeutics Market"Analysis Report: www.goo.gl/GHrjFv

Rise in the Global Geriatric Population is Driving the Vitamin Tonics Market

Vitamin tonics are known for their ability to strengthen and invigorate the body tone of a human being. They are being utilized for the prevention and treatment of various deficiency conditions including rickets, osteomalacia, angular stomatitis, and anemia. They are available in different forms such as syrupy semisolids, liquids, capsules, tablets, pills, and multivitamin injections. It is being observed that the tonics in liquid state are mostly preferred because of higher patient compliance and acceptance amongst the children.

The doctors usually prescribe and suggest these products for the state of vitamin deficiency anemia including folate deficiency anemia, pernicious anemia and vitamin C deficiency anemia. Another important factor that is driving the demand of these products may include hectic lifestyle of people around the world.

People can compensate with their poor dietary habits and lack of exercise intake by just following the regular intake intervals of vitamin tonics. And that has augmented the consumption level of these products worldwide.

View Summary Of This Report Click Here:

 www.grandviewresearch.com/industry-analysis/vitamin-tonics-market

Rise in the global geriatric population is also driving the vitamin tonics market globally to its peak. Segmentation by the product type includes Syrup, Capsules, Tablets, and Multivitamin injections. Segmentation by the distribution channel includes Hospitals Clinics, Retail Pharmacies and Drug Stores, E-commerce, Public Hospitals, and Private Clinics.

There is a significant growth in the vitamin tonics market because of the increase in the tendency of people to spend more for preventive measures. They are opting for precautionary measures rather than treating the illness later on and facing the outcomes. The awareness level about health has risen among the masses and the availability of products that are highly affordable has also come up. The companies are trying to spend a great deal for the education of people and that has ultimately increased their awareness about the merits of having vitamin tonics.

Segmentation By Region spans North America, Europe, Asia Pacific, Japan, and MEA. For the vitamin tonics, the U.S. market is said to be developing; though with a slow and steady rate. The major factor that can be attributed to this growth could be the customers questions regarding the actual benefits and advantages associated with the product.

To learn more about this report: www.goo.gl/7BeoWX

Bioanalytical Testing Services Market Based on Molecule Type

The global Bioanalytical Testing Services Market is anticipated to reach USD 3.0 billion by 2025, according to a new report by Grand View Research, Inc. The performance of market players in bioanalytical testing domain is highly influenced by the level of demand from end-user side. Due to intense market efforts, increasing awareness level, improving accessibility, and government initiatives, consumers, these days, are more concerned about self-care, resulting in higher consumption of pharmaceutical products. 

There is a major price difference observed between conducting analytical tests in-house and outsourcing. A company may lack the required set-up and expertise to perform every possible test in-house. In addition, there are serval no routine activities that are needed to be performed only once. These include registration stability storage & testing, process & facility validation work, cleaning validations, analytical testing using expensive equipment & method development.

View Summary Of This Report Click Here: www.grandviewresearch.com/industry-analysis/bioanalytical-testing-services-market

The bioanalytical testing services market based on molecule type is bifurcated into small molecule testing and large molecule testing. Small molecule bioanalytical testing held a lucrative share in 2016. Most of the generic and branded drug compounds are of small molecule category. Additionally, with the patent expiration many blockbuster drugs, generic manufacturers are required to conduct and submit bioanalytical testing results. These factors primarily governed the growth of the small molecule drug bioanalytical testing market. On the contrary, large molecule bioanalytical testing services are anticipated to exhibit healthy growth over the forecast period. This can be attributed to a rich pipeline of biologics or amino acid based products.

Further Key Findings From the Study Suggest:

• Large molecule bioanalytical testing services are anticipated to exhibit healthy growth over the forecast period. This can be attributed to a rich pipeline of biologics or amino acid based products
• LC-MS studies are vital in bioanalysis of large molecules. They can be used for various methods such as development & validation, preclinical & clinical sample analysis, immunoanalytical solutions, and microfluidic tests for biologics
• In vivo ADME is designed to assess biopharmaceutical characteristic of a drug at preclinical level. Service providers offer customized study on variety of species. QWBA, mass balance, excretion, expired air collection in rodents, metabolite profiling, and radioactivity sample analysis are the key studies offered
• North America dominated the global bioanalytical testing services market in 2016. This can be attributed to the fact that it is one of the top manufacturing hubs of highly reliable, complex, and high-end pharmaceuticals
• Some of the key players in this market include PPD, ICON plc., Covance Inc., LabCorp, Charles River Laboratories International, Inc., inVentiv Health, SGS SA, Toxikon, Inc., Intertek group, and Pace Analytical Services, LLC.Collaborations, service portfolio expansion and merger & acquisitions are key strategic undertakings by these players

To learn more about this report: www.goo.gl/ZM3BgA

Pharmaceutical Packaging Market Comprises Wide Array of Products & Demand Grows rapidly

The global Pharmaceutical Packaging Market is expected to reach USD 158.8 billion by 2025, according to a new report by Grand View Research, Inc. The growing demand for pharmaceuticals coupled with increased emphasis on product packaging is expected to drive market growth.

Pharmaceutical packaging market comprises wide array of products. The demand for these products is expected to grow rapidly on account of fortification of medicines and drugs against exterior impacts. However, the packaging materials and products need to bear the brunt of stringent government regulations and growing market for counterfeit pharmaceuticals. Counterfeit pharmaceuticals are expected to pose a major threat to manufacturers.

View Summary Of This Report Click Here: www.grandviewresearch.com/industry-analysis/pharmaceutical-packaging-market

North America is a dominant region in the market backed by thriving pharmaceutical industry and rapid new product introduction. Asia Pacific is anticipated to grow rapidly on account of rising pharmaceutical manufacturing in China and India. The growing trend of contract packaging in the pharmaceutical industry is expected to further augment market growth in Asia Pacific.

Further key findings from the report suggest:

• Aluminum foil material segment is projected to grow at a CAGR of 7.2% from 2017 to 2025 owing to rising demand for packaging of special purpose drugs.
• Paper and paperboard is the second largest product segment and is expected to reach USD 40.83 billion by 2025 due to growing demand in secondary packaging products.
• Blister packs in the primary pharmaceutical packaging product category is expected to grow at a CAGR of 9.2% from 2017 to 2025 on account of growing demand in oral drugs.
• The market share of Asia Pacific is expected to reach 33% in 2025 owing to growing demand for pharmaceuticals and presence of large number of plastic manufacturers
• The Middle East & Africa region is expected to grow at a CAGR of 5.6% from 2017 to 2025 backed by growing demand for medicines in Tanzania, Nigeria and South Africa.
• The market is highly dispersed due to the presence of a large number of small and large manufacturers

To learn more about this report: www.goo.gl/m4EL3b

Pneumonia Therapeutics Market Grows at an Unprecedented Rate Owing to the Increasing Prevalence of Pneumococcal Disease Globally

The global pneumonia therapeutics market is expected to reach USD 22.9 billion by 2025, according to a new report by Grand View Research, Inc. This market is anticipated to grow at an unprecedented rate owing to the increasing prevalence of pneumococcal disease globally. The increasing demand for pneumonia therapeutics is a result of unmet clinical needs in emerging as well as developed regions. Increasing focus of healthcare organizations on raising awareness and issuing guidelines for efficient management of pneumococcal disease is predicted to broaden the scope for growth over the coming years.For instance, Infectious Diseases Society of America/American Thoracic Society has issued guidelines on the management of community-acquired pneumonia. According to a white paper released by American Academy of Family Physicians, adherence to these guidelines has resulted in positive patient outcomes during the treatment of community-acquired bacterial pneumonia in patients.

View Summary Of This Report Click Here: www.grandviewresearch.com/industry-analysis/pneumonia-market

Moreover, growing R&D activities in life sciences are anticipated to create positive impact on the market over the coming years. Consequentially, increase in number of products, currently being reviewed under clinical trials, is anticipated to fuel the overall growth.In the present scenario, there are 12 drugs under investigation in phase III trials, 4 drugs under phase II, and 3 drugs under phase I trial. The aforementioned factors exemplify the consistent efforts being made by the market players. For instance, Omadacycline, a tetracycline under phase III clinical trial, developed by Paratek Pharmaceuticals is being investigated for use in the treatment of ventilator-associated and community-acquired bacterial pneumonia.

Further Key Findings From the Report Suggest:

• Vaccines accounted for the largest share in the product segment in 2016. This can be attributed to their high efficacy and growing inclination of patients toward preventive measures
• They are also expected to grow at a lucrative rate owing to the recommendation by WHO for their inclusion in national immunization programs
• Drugs are expected to witness moderate growth rate throughout the forecast period. This is believed to be a result of the infiltration of generic drugs that are more cost-efficient.
• North America accounted fora substantial share in the market owing toincreasing number of supportive government initiatives and high awareness levels amongst the end-users
• Asia Pacific is expected to witness exponential CAGR during the forecast period owing to its high disease burden and continual infrastructural upgradation of research & manufacturing facilities in the region
• High competition has been observed in the market, where major players adopt strategies such as new product development, collaborations,and strategic agreements to gain market share

To learn more about this report: www.goo.gl/z9BcFx

Clinical Trial Supplies Market is Slowly Shifting from Developed Nations to Emerging Countries

The global clinical trial supplies market is expected to reach USD 3.3 billion by 2025, according to a new report by Grand View Research, Inc. The market is expected to witness growth at 7.3% CAGR owing to Increasing volume of clinical trial studies coupled with the growing complexity in conduction of these trials are the primary driver of the industry. Furthermore, geographic expansion and development of Information Technology (IT) to facilitate higher integration and smooth performance of activities are other vitally impacting parameters. Over the next eight years, the clinical trials and pharmaceutical industry is anticipated to continue steady growth, thereby promoting the high requirement of clinical trial supplies.

View Summary Of This Report Click Here: www.grandviewresearch.com/industry-analysis/clinical-trial-supplies-market

U.S and Canada are home to majority of clinical trials which are conducted in this region. No language barrier is one of the major factor for the preference of this region for majority of clinical trials, as English language is widely spoken in this region. Major CRO’s and biopharmaceutical companies have their hub in this region and with advancement in technology the demand for efficient supplies are increasing and the region is expected to dominate the clinical trial supplies market over the forecast period.

Further Key Findings From the Study Suggest:

• On the basis of clinical phase, the market is anticipated to be dominated by Phase III in 2025. The presence of large number of molecule estimated to reach Phase III by 2020 is the primary factor responsible for this prediction.
• By services, storage and distribution is anticipated to witness the fastest growth at a CAGR of over 7.0%.
• Key end-users of this industry are pharmaceuticals, and biologics. Biologics are expected to witness fastest growth owing to the increasing research in the field of genetics and biotechnology such as development of nanoparticle based drug delivery systems.
• In terms of therapeutic use or clinical indication, oncology dominates the market. The highest research activity as of 2016 is being performed for this indication, which in turn is expected to drive the market.
• Few of the industry players include Movianto GmbH, Thermo Fischer Scientific, Sharp Packaging Services, Catalent Pharma Solution, Biocair International Ltd., PCI Services, Almac Group Ltd, and Patheon Inc. Other players present in the market space include Clinigen Group Plc, Merck Serono, and Chimerix.

To learn more about this report: www.goo.gl/Mn2CaC